More C-Suite level pharma executives are lending their domain expertise to private equity firms, which then use their skills for commercial due diligence on targets or in an operating partner role in portfolio companies once a deal is sealed. PEs are also increasingly opting for control deals, at least in India, with an aim to run the acquired firm professionally thereon.

India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral take multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.

Oncology partnership with Swiss major follows late 2020 pact with Merck KGaA. Pfizer divests Phase Ib breast cancer candidate to Celcuity.

Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.